AptaBio Financial Statements From 2010 to 2024

293780 Stock   6,520  210.00  3.12%   
AptaBio Therapeutics financial statements provide useful quarterly and yearly information to potential AptaBio Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on AptaBio Therapeutics financial statements helps investors assess AptaBio Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AptaBio Therapeutics' valuation are summarized below:
AptaBio Therapeutics does not presently have any fundamental signals for analysis.
Check AptaBio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AptaBio Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . AptaBio financial statements analysis is a perfect complement when working with AptaBio Therapeutics Valuation or Volatility modules.
  
This module can also supplement various AptaBio Therapeutics Technical models . Check out the analysis of AptaBio Therapeutics Correlation against competitors.

AptaBio Therapeutics Company Shares Outstanding Analysis

AptaBio Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current AptaBio Therapeutics Shares Outstanding

    
  10.88 M  
Most of AptaBio Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AptaBio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition
Based on the latest financial disclosure, AptaBio Therapeutics has 10.88 M of shares currently outstending. This is much higher than that of the sector and significantly higher than that of the Biotechnology & Medical Research industry. The shares outstanding for all Republic of Korea stocks is notably lower than that of the firm.

AptaBio Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining AptaBio Therapeutics's current stock value. Our valuation model uses many indicators to compare AptaBio Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AptaBio Therapeutics competition to find correlations between indicators driving AptaBio Therapeutics's intrinsic value. More Info.
AptaBio Therapeutics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value AptaBio Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AptaBio Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About AptaBio Therapeutics Financial Statements

AptaBio Therapeutics stakeholders use historical fundamental indicators, such as AptaBio Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although AptaBio Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in AptaBio Therapeutics' assets and liabilities are reflected in the revenues and expenses on AptaBio Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AptaBio Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

Pair Trading with AptaBio Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AptaBio Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AptaBio Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with AptaBio Stock

  0.72225220 GenolutionPairCorr

Moving against AptaBio Stock

  0.4105560 KB Financial GroupPairCorr
The ability to find closely correlated positions to AptaBio Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AptaBio Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AptaBio Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AptaBio Therapeutics to buy it.
The correlation of AptaBio Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AptaBio Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AptaBio Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AptaBio Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in AptaBio Stock

AptaBio Therapeutics financial ratios help investors to determine whether AptaBio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AptaBio with respect to the benefits of owning AptaBio Therapeutics security.